COX Nicox SA

Nicox Announces Improved Financial Terms from Bausch + Lomb for VYZULTA

Nicox Announces Improved Financial Terms from Bausch + Lomb for VYZULTA

Press Release
Nicox Announces Improved Financial Terms from Bausch + Lomb for VYZULTATM
Increase in Royalties by 1% on Annual VYZULTATM Global Sales Revenue Over $300 Million Additional $20 Million in Potential Milestones ................................................



 



March 14, 2018 - release at 7:30 am CET

Sophia Antipolis, France



Nicox SA (Euronext Paris: FR0013018124, COX), international ophthalmology company, today announced an amendment to its global licensing agreement with Bausch + Lomb Incorporated, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International Inc., concerning VYZULTATM (latanoprostene bunod ophthalmic solution), 0.024%.



Under the original agreement signed in 2010, Bausch + Lomb would have paid Nicox royalties of 10% to 15% on worldwide Net Sales of VYZULTATM, comprising three tiers of royalties triggered by increasing, pre-defined annual sales levels.  In consideration of final resolution and release relating to certain alleged issues between the parties, the amendment provides that, from January 1, 2019 the royalties due to Nicox according to the original agreement will increase by 1% over the original royalty on Net Sales above $300 million per year.  Royalties will now be 10% to 16% over four tiers, reaching the maximum tier if and when global Net Sales exceed $500 million annually.  Taking into account Nicox's royalty payments to Pfizer1, the net royalties to Nicox will be 6% to 12%, compared to 6% to 11% originally. 



In addition, the potential milestones payable to Nicox by Bausch + Lomb have been increased by $20 million, added to and split between 3 existing milestones at increasing annual Net Sales levels.  The first additional amount payable will be added to the milestone on achievement of $300 million annual Net Sales and the last additional amount payable will be added to the milestone on achievement of $700 million annual Net Sales.  The total potential milestones due to Nicox have therefore been increased from $145 million to $165 million2,3.  The next sales milestone due from Bausch + Lomb remains as originally agreed at $20 million upon VYZULTATM Net Sales reaching $100 million, with $15 million of this milestone paid to Pfizer4,5.



VYZULTATM was launched in the U. S. by Bausch + Lomb in December 2017.



About VYZULTATM (latanoprostene bunod ophthalmic solution), 0.024%



VYZULTATM, approved by the U.S. Food and Drug Administration (FDA) on November 2, 2017, is a prostaglandin analog indicated for the reduction of IOP in patients with open angle glaucoma or ocular hypertension.  It is the first prostaglandin analog with one of its metabolites being nitric oxide (NO). Following topical administration, VYZULTATM, a once daily monotherapy with a dual mechanism of action, works by metabolizing into two moieties, latanoprost acid, which primarily works within the uveoscleral pathway to increase aqueous humor outflow, and butanediol mononitrate, which releases NO to increase outflow through the trabecular meshwork and Schlemm's canal.  The most common ocular adverse reactions with incidencesuperior or equal to 2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%).



 



Notes Net of royalty due to Pfizer per the agreement in note 4 below $15 million related to the development of a combination product involving latanoprostene bunod Milestones relating to regulatory approvals, achievement of sales targets and future development steps Per the terms of the contract signed with Pfizer in August 2009 by which Nicox recovered the rights to latanoprostene bunod No further milestones payable to Pfizer
About Nicox
Nicox S.A. is an international ophthalmic company, with two out-licensed commercial-stage products, developing innovative solutions to help maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel drug candidates that target multiple ophthalmic conditions, including glaucoma. Nicox currently has two products with approved New Drug Applications, VYZULTATM (latanoprostene bunod ophthalmic solution) 0.024%, licensed worldwide to Bausch + Lomb, and ZERVIATETM (cetirizine ophthalmic solution) 0.24%, licensed in the U.S. to Eyevance.  In addition, our promising drug-candidate pipeline includes clinical stage assets based both on our proprietary NO-donating research platform and on the repurposing of existing molecules as well as a next-generation of stand-alone nitric-oxide donors and exploratory novel NO-donating compounds with the potential to offer novel approaches to treat a range of ophthalmic conditions. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.



For more information on Nicox, its products or pipeline, please visit: .
Analyst coverage
Bryan, Garnier & Co   Hugo Solvet   Paris, France

Invest Securities   Martial Descoutures   Paris, France

Gilbert Dupont   Damien Choplain   Paris, France



 
 
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Upcoming financial and business conferences
 



March 20-21  Oppenheimer's 28th Annual Healthcare Conference  New York, USA

April 8-10  HC Wainwright Global Biotechnology Conference  Monaco, Principality of Monaco

April 16-17  SmallCap Event   Paris, France

May 29  Conférence Gilbert Dupont 16th Annual Healthcare   Paris, France

June 27-28  European MidCap Event   Paris, France

October 1-3  Conférence Cantor Global Healthcare  New York, USA
Contacts
Nicox

Gavin Spencer,

Executive Vice President Corporate Development

T +33 (0)4 97 24 53 00

Investor Relations

Europe

Nicox

Corporate Communications Department

T +33 (0)4 97 24 53 00





 
Media Relations

United Kingdom

Jonathan Birt

T 6

United States

Argot Partners

Melissa Forst

T +1 (212) 600-1902

France

NewCap

Nicolas Merigeau

T +33 (0)1 44 71 94 98

 



 



 
United States

Argot Partners

David Rosen

T +1 (212) 600-1902





 
Disclaimer
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.



Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the 'Document de référence, rapport financier annuel et rapport de gestion 2016' filed with the French Autorité des Marchés Financiers (AMF) on March 29, 2017, and in the updated and additional risk factors as of August 14, 2017, which are available on Nicox's website ().
Nicox S.A.

Drakkar 2

Bât D, 2405 route des Dolines

CS 10313, Sophia Antipolis

06560 Valbonne, France

T +33 (0)4 97 24 53 00

F +33 (0)4 97 24 53 99

Attachment:

EN
14/03/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nicox SA

 PRESS RELEASE

Nicox : Assemblée Générale Ordinaire et Extraordinaire 2024

Nicox : Assemblée Générale Ordinaire et Extraordinaire 2024 Communiqué de presseNicox : Assemblée Générale Ordinaire et Extraordinaire 20249 avril 2024 – diffusion à 17h30 Sophia Antipolis, FranceNicox SA (Euronext Paris : FR0013018124, ALCOX, éligible PEA-PME), société internationale spécialisée en ophtalmologie, informe ses actionnaires que l’Assemblée générale ordinaire et extraordinaire convoquée sur première convocation le mercredi 10 avril 2024 ne pourra pas délibérer faute de réunir le quorum requis.Les actionnaires de la Société sont en conséquence convoqués en Assemblée générale or...

 PRESS RELEASE

Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting

Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting Press Release Nicox: 2024 Ordinary and Extraordinary Shareholder MeetingApril 9, 2024 – release at 17:30 CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, informs its shareholders that the Ordinary and Extraordinary general meeting convened on first call on Wednesday April 10, 2024, will not be held as the quorum required by law has not been reached.The shareholders of Nicox are thus convened on second call for an Ordinary and Extraordinary general meeting on the same...

 PRESS RELEASE

Number of voting rights as of March 31, 2024

Number of voting rights as of March 31, 2024 Nicox SA Société anonyme with a registered capital of € 50,299,694  Head Office: Sundesk Sophia Antipolis, Emerald Square, rue Evariste Galois – 06410 BiotR.C.S. ANTIBES 403.942.642  On April 2nd, 2024,  MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS  (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF)   As of March 31, 2024Total number of shares composing the share capital 50,299,694 Total number of voting righ...

 PRESS RELEASE

Nicox's Shareholder Letter

Nicox's Shareholder Letter Dear Shareholder, The upcoming Extraordinary General Meeting, which will take place on April 10, is of particular importance for Nicox. I am writing to you today, in my capacity as the new Chief Executive Officer, in order to share the latest information with you and request your participation in this meeting, as your support is essential to provide the Company with new momentum. It is an honor to have the trust of the Board of Directors in appointing me CEO of Nicox. Many of you know me personally, as I have been part of the company for nearly 20 years. As su...

 PRESS RELEASE

Nicox - Lettre aux Actionnaires

Nicox - Lettre aux Actionnaires Madame, Monsieur, Cher Actionnaire, L’Assemblée générale ordinaire et extraordinaire convoquée pour le 10 avril prochain est d’une importance particulière pour Nicox. Je vous écris aujourd'hui en ma qualité de nouveau Directeur général afin de vous présenter des informations récentes sur la Société et solliciter votre participation à cette assemblée car votre soutien est crucial pour donner un nouvel élan à Nicox. C'est un honneur pour moi d'avoir la confiance du Conseil d'administration avec cette nomination en qualité de Directeur général. Beaucoup d'entr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch